BABA
Alibaba Group Holding Limited
BABA's fundamentals are weak: its operating margin fell 10 points to 4.2% and free cash flow turned negative, though revenue grew 4.3%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
CHSN
Chanson International Holding
There isn't enough reported data to score CHSN yet.
BABA Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Weak | |
| Healthy |
BABA's balance sheet is currently healthy, and its revenue is stable, but its profitability and cash flow are under pressure.
CHSN Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Strong | |
| Unavailable | |
| Strong |
CHSN's profitability and balance sheet are currently strong. There isn't enough data to rate its revenue and cash flow.
BABA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 16x | $69.66 | -26% |
| Fair | 20x | $86.59 | -8.2% |
| Current | 21x | $94.36 | — |
| Expensive | 26x | $115 | +22% |
Historical ranges are pointers, not guarantees.
BABA's PE is 21x, but its earnings don't support one, so it isn't a reliable read right now.
CHSN PE Valuation
CHSN has no meaningful PE right now: it lost money over the past year.
BABA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for BABA, with profitability improving. However, they disagree widely on these estimates.
CHSN Forward outlook
There aren't enough analyst estimates for CHSN to show an outlook.
BABA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $4.42 | -52% |
| Q1 2026 | $6.57 | -18% |
| Q4 2025 | $5.79 | -22% |
| Q3 2025 | $7.85 | +49% |
| Q2 2025 | $9.27 | +116% |
| Q1 2025 | $8.06 | +71% |
| Q4 2024 | $7.47 | +24% |
| Q3 2024 | $5.26 | -35% |
BABA's earnings per share have fallen from their peak: $4.42 over the past year, against $9.27 in mid-2025. Its recent earnings include one-off gains.
CHSN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2024 | $400.00 | +1567% |
CHSN and BABA do not have enough comparable growth data to identify a winner.
BABA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $40.2B | +8.3% |
| Q1 2026 | $36.5B | +2.9% |
| Q4 2025 | $42.7B | +1.7% |
| Q3 2025 | $37.2B | +4.8% |
| Q2 2025 | $37.2B | +1.8% |
| Q1 2025 | $35.5B | +6.6% |
| Q4 2024 | $42B | +7.6% |
| Q3 2024 | $35.5B | +5.2% |
BABA's revenue has grown year over year for 16 quarters in a row: $40.2B last quarter, up 8.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 7.2% | -6.9 points |
| Q1 2026 | -0.3% | -12 points |
| Q4 2025 | 7.1% | -7.6 points |
| Q3 2025 | 2.2% | -13 points |
| Q2 2025 | 14% | -0.7 points |
| Q1 2025 | 12% | +5.4 points |
| Q4 2024 | 15% | +6.1 points |
| Q3 2024 | 15% | 0 points |
BABA has the edge over CHSN on profitability, with a higher operating margin.
CHSN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $8.3M | -4.5% |
| Q4 2025 | $9.6M | -10% |
| Q2 2025 | $8.7M | +15% |
| Q4 2024 | $10.7M | +27% |
| Q2 2024 | $7.5M | -14% |
| Q4 2023 | $8.4M | +79% |
| Q2 2023 | $8.8M | +3.1% |
| Q4 2022 | $4.7M | -41% |
CHSN has the edge over BABA in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -9.4% | -2 points |
| Q4 2025 | -7.3% | +1.3 points |
| Q2 2025 | -14% | -15 points |
| Q4 2024 | 0.3% | +32 points |
| Q2 2024 | -7.4% | -6.9 points |
| Q4 2023 | -8.6% | -4.6 points |
| Q2 2023 | 1.3% | +5.3 points |
| Q4 2022 | -32% | -20 points |
CHSN's operating margin was −9.4% last quarter, down 2 points from the same quarter a year ago.
BABA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$6.7B | -$4.1B |
| Q1 2026 | -$2.7B | +$1.5B |
| Q4 2025 | $1B | -90% |
| Q3 2025 | -$3.2B | -254% |
| Q2 2025 | -$2.7B | -182% |
| Q1 2025 | -$4.2B | -12231% |
| Q4 2024 | $10.4B | -4.8% |
| Q3 2024 | $2.1B | -62% |
BABA's free cash flow has turned negative after years in the green: −$11.6B over the past year.
CHSN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2024 | $2.2M | +$6.4M |
| Q2 2024 | $771.9K | +68% |
| Q4 2023 | -$4.2M | -778% |
| Q2 2023 | $458.1K | +$1.4M |
| Q4 2022 | $617.7K | +$1M |
| Q2 2022 | -$926.4K | -738% |
| Q4 2021 | -$405.1K | -164% |
| Q2 2021 | $145.3K | +263% |
CHSN's free cash flow was −$4M over the past year, against −$255,670 the year before.
BABA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +11.1M shares |
| 1 year | +0.9% | +21.4M shares |
| 3 years | -6.2% | -161M shares |
| 5 years | -12% | -339M shares |
| Available history | -8.4% | -221M shares |
BABA has the edge over CHSN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | $269.8M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
BABA spent $270M buying back its own shares over the past year, after none the year before.
CHSN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +85094% | +1.3M shares |
| 1 year | +730% | +1.2M shares |
CHSN has 1M diluted shares, up 730% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q4 2022 | — |
| Q2 2022 | — |
| Q4 2021 | — |
| Q2 2021 | — |
| Q4 2020 | — |
| Q2 2020 | — |
| Q4 2019 | — |
BABA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.5x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.8x | Very low |
| Q2 2025 | 0.2x | Very low |
| Q1 2025 | 0.3x | Very low |
| Q4 2024 | 0.1x | Very low |
| Q3 2024 | -0.2x | Net Cash |
BABA's net debt is less than a year of its operating earnings (EBITDA).
CHSN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2024 | -36.0x | Net Cash |
CHSN has more cash than debt.
BABA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.0 | Neutral |
| Stochastic | 12.7 | Oversold |
BABA's weekly RSI is 38 (neutral) and its Stochastic is 13 (oversold).
CHSN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.6 | Neutral |
| Stochastic | 35.1 | Neutral |
CHSN's weekly RSI is 33 (neutral) and its Stochastic is 35 (neutral).
BABA PE vs Consumer Cyclical Sector
| Metric | BABA | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 18x | 19% above |
| PE % | 60 | 47 | 13 pts above |
BABA is trading at 21x earnings, a 19% premium to the Consumer Cyclical sector's median of 18x, though its earnings don't support one.
CHSN PE vs Consumer Cyclical Sector
| Metric | CHSN | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 18x | — |
CHSN has no meaningful PE right now: it lost money over the past year.
BABA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $104.7 | 9.9% below |
| 20 week MA | $111.1 | 15% below |
| 50 week MA | $128.0 | 26% below |
| 100 week MA | $127.7 | 26% below |
| 200 week MA | $106.4 | 11% below |
CHSN has stronger trend alignment. BABA is above 0 of 5 weekly averages versus CHSN above 0 of 4.
CHSN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.25 | 52% below |
| 20 week MA | $1.15 | 48% below |
| 50 week MA | $92.1 | 99% below |
| 100 week MA | $3,017.9 | 100% below |
CHSN is in a downtrend: it's below all four of its weekly moving averages, and 100% below its 100-week average.
BABA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $215.5 | $222.0 | +3% |
| 2021 | $222.0 | $118.7 | -47% |
| 2022 | $118.7 | $85.7 | -28% |
| 2023 | $85.7 | $77.5 | -9.5% |
| 2024 | $77.5 | $85.1 | +9.7% |
| 2025 | $85.1 | $152.2 | +79% |
| 2026 YTD | $152.2 | $94.4 | -38% |
BABA has the edge over CHSN on returns for 2026, with the stronger performance.
CHSN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2023 | $16,880.0 | $9,760.0 | -42% |
| 2024 | $9,760.0 | $46,320.0 | +375% |
| 2025 | $46,320.0 | $209.0 | -100% |
| 2026 YTD | $209.0 | $0.60 | -100% |
CHSN's yearly returns have swung widely, from +375% in 2024 to −100% in 2025. It's down 100% so far in 2026.